Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist - Wikidata - thesis-toulmin - TriplyDB

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist

http://www.wikidata.org/entity/Q28379390

about

Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP Molecular mechanisms of antidiuretic effect of oxytocin Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists How genetic errors in GPCRs affect their function: Possible therapeutic strategies Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Single amino acid substitutions and deletions that alter the G protein coupling properties of the V2 vasopressin receptor identified in yeast by receptor random mutagenesis.Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.The treatment of hyponatraemia using vasopressin antagonists.Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension.Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists.Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.Enantioselective Synthesis of Spiro[cyclohexane-1,3'-indolin]-2'-ones Containing Multiple Stereocenters via Organocatalytic Michael/Aldol Cascade Reactions.Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells.Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin Mass-spectrometry-based method for screening of new peptide ligands for G-protein-coupled receptors.Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats.Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin.Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease.Vaptans and hyponatremia in critical patients Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.Generation and phenotype of mice harboring a nonsense mutation in the V2 vasopressin receptor gene.Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).The potential role for lixivaptan in heart failure and in hyponatremia.Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor.Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study.Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.cAMP-dependent chloride secretion mediates tubule enlargement and cyst formation by cultured mammalian collecting duct cells.Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.Posttranscriptional control of aquaporin-2 abundance by vasopressin in renal collecting duct principal cells.Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas.Cyclic AMP is sufficient for triggering the exocytic recruitment of aquaporin-2 in renal epithelial cells Downregulation of vasopressin V1A receptors and activation of mitogen-activated protein kinase in rat mesangial cells cultured under high-glucose conditions.Effect of small molecule vasopressin V1a and V2 receptor antagonists on brain edema formation and secondary brain damage following traumatic brain injury in mice.

P2860

Q22254440-09D9B21D-FC5C-4574-9B2F-43596619A3DC Q24649233-2772D828-1748-4358-94EE-10F6CD543862 Q26776120-D752F2BD-E2AC-41E9-B2BE-A19B6B52ECFA Q26992276-FA4796F9-8FDD-42C6-B5A3-C3D3A2345353 Q28115855-0D82D435-46C2-4689-9E5B-83D3D865C0AE Q28344194-0CE611E8-9402-4DD5-9B12-F1C0744C1731 Q28367906-571F487D-7E04-4AD1-B240-CE0D321B901F Q28571242-DA350D0D-6AF4-431E-8DC3-A6CA3176A59F Q28646207-58889C30-CBDC-42EA-9C65-430F1BDA4776 Q28659266-BE4EB321-80CB-45C4-BEE2-FAA2E84C3922 Q29617768-81476ADF-29AF-4730-A8F5-111C9E528B5A Q30486707-D9515787-8BFB-4593-8B7A-0159266C0D1A Q30662392-D88D5B19-2990-4FE9-AD35-B3349A26E8CD Q31398937-73E70BFF-1387-48EA-AD11-35AD25732842 Q33906415-97A0992B-B47A-42F3-9390-6FD3D4E1781E Q33906421-568E09D5-CFBB-4560-9AEA-68DB7FB9CFC8 Q34232014-4F919A89-8500-4324-B7F2-9742A97221D6 Q34257617-F963E4BD-2EDD-4DC2-ACCF-36CB36AE539C Q35104226-F394EE7F-A889-4EC6-B800-1C056E5A21E8 Q35107577-D50D800D-1F37-4943-80B9-7B2996AB0EA0 Q35543229-ECB117CA-531F-4D1A-B5ED-B04E73BE2EC2 Q35620956-093189A9-5AF2-4C4F-994B-79C3AAF15843 Q35621908-ACBA8BC4-E04F-4871-813C-F029A725DD97 Q36229143-9CA8393A-D9E0-4CF1-B87C-383CCF3B125A Q36600774-F5809414-3179-41E3-ACE7-78EE73230B1B Q37058365-819F3A55-0C0C-45B8-859F-A7A64FABF5AE Q37265054-C9E1B782-4D26-44BF-812E-A24F11AB9A36 Q37271697-1E3E7D2C-E312-433F-B8C6-B7878B47B7A5 Q37843827-02A52BD8-F260-4AF9-BA90-F6A9F024404D Q37872778-B833A5F2-53C7-4B86-99AA-2AF2FB0BAEFD Q38331968-675C946C-904B-4BC8-9235-DEE2FE596F91 Q38496208-1130A1C0-2AE8-42B1-A8D6-4CD826ED6E83 Q39890679-9B189985-6CD0-4E12-A6D0-503BE09E2CC8 Q39909565-1182505E-B9E6-4901-B326-FC2EBA9D18CB Q40240733-49B128C4-C1D5-4073-9A52-6FBFFD12BBAB Q40403841-25AF570B-514A-42AC-8F8D-9253BFA03915 Q40649344-11BBABEB-3CD4-4914-9EA7-313C721B002E Q40663356-6C6E7313-6F76-411A-803E-36E50CD33EC3 Q42502411-7CA957DF-82C2-4E39-A325-D9A0DA8020C8 Q43139485-16E3E579-B246-42AD-B9FA-DD416D0FE406

P2860

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist

http://www.wikidata.org/entity/Q28379390

description

1996 nî lūn-bûn

@nan

1996 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Characterization of SR 121463A ...... pressin V2 receptor antagonist

@ast

Characterization of SR 121463A ...... pressin V2 receptor antagonist

@en

Characterization of SR 121463A ...... pressin V2 receptor antagonist

@nl

type

label

Characterization of SR 121463A ...... pressin V2 receptor antagonist

@ast

Characterization of SR 121463A ...... pressin V2 receptor antagonist

@en

Characterization of SR 121463A ...... pressin V2 receptor antagonist

@nl

prefLabel

Characterization of SR 121463A ...... pressin V2 receptor antagonist

@ast

Characterization of SR 121463A ...... pressin V2 receptor antagonist

@en

Characterization of SR 121463A ...... pressin V2 receptor antagonist

@nl

P1433

Q28379390-54985825-06CB-4E1C-AF21-300131C21B0E

P1476

Q28379390-F016775A-04EB-44D7-8A04-A4024EB9FAD5

P2093

Q28379390-04E7510E-0151-4348-AE93-7E339922D720

Q28379390-06DD5A65-A598-4EA6-B8E0-06E41193B42E

Q28379390-070B6563-A8C8-4DE0-A5A6-95B19792421B

Q28379390-1395610F-F5E2-4CDE-B7A6-38D1FF5107C7

Q28379390-1461E642-9F20-4A76-8B34-59B4182C62F0

Q28379390-2E5169E4-7FDE-455D-BD8F-BD29EB0A1ABA

Q28379390-359F5A41-9F80-49AA-B47D-816E96177A0E

Q28379390-424092E3-C9B1-44E1-A80A-236DDCEBB4D7

Q28379390-518E4556-8D7E-4C24-BFBA-E48412528A2A

Q28379390-52CDE494-278C-4C92-9A01-989A62EA7782

P2860

Q28379390-09504483-139E-4322-9C95-2950FB1F7077

Q28379390-21E285F3-0C87-488D-9F06-7ABF573D4ABB

Q28379390-2BEACA74-BB7C-4E79-B218-D880AA5E963D

Q28379390-30BE8349-207A-4F74-810D-84EC05305DBC

Q28379390-31A38CD6-FD8A-4F41-98AB-836E9D4C2F57

Q28379390-342E3CC4-1817-477C-9062-AC9214B36007

Q28379390-3CFC9251-8AED-4702-A8AD-C3E9F7767989

Q28379390-40C5CD11-5D5A-4B93-A864-1CE95AEF74E9

Q28379390-45FC08C1-2427-4C4B-AB87-DB6D4B740480

Q28379390-497CE376-0CCF-4730-923E-78A07860C6CE

P304

Q28379390-A7316B10-E70D-49EE-B4BA-9ACFF1A6B268

P31

Q28379390-5AAA3418-5CED-4347-9FDA-1C8BC3C05F4D

P356

Q28379390-82B32147-205B-44C8-B55C-9B5C8E6D3EDF

P407

Q28379390-0BB53A94-C66D-49D1-AA07-8B282F93C66F

P433

Q28379390-EFAF8420-F3BB-4CC8-B930-EBE04FE965FB

P478

Q28379390-50071D6D-D1F3-4282-B83A-2EA38CCFE05C

P577

Q28379390-6CE194FD-D3C5-4B98-81B2-C4F75D67332E

P5875

Q28379390-0D6DC54A-B288-4F34-9E53-07EC25FFA761

P698

Q28379390-FAB0834D-9737-4351-B61A-0C0B4080A551

P921

Q28379390-8fe4c649-fa2c-4fb8-8e8d-c55c7a2907d5

P932

Q28379390-328AF731-D038-449C-90FB-988A3385F7BF

P356

P1433

Journal of Clinical Investigation

P1476

Characterization of SR 121463A ...... pressin V2 receptor antagonist

@en

P2093

B Pouzet

http://www.w3.org/2001/XMLSchema#string

C Barberis

http://www.w3.org/2001/XMLSchema#string

C Garcia

http://www.w3.org/2001/XMLSchema#string

C Lacour

http://www.w3.org/2001/XMLSchema#string

C Serradeil-Le Gal

http://www.w3.org/2001/XMLSchema#string

D Chicot

http://www.w3.org/2001/XMLSchema#string

D Nisato

http://www.w3.org/2001/XMLSchema#string

D Raufaste

http://www.w3.org/2001/XMLSchema#string

E Marty

http://www.w3.org/2001/XMLSchema#string

G Brossard

http://www.w3.org/2001/XMLSchema#string

P2860

Neurohypophysial Hormones in the Adrenal Medulla*

Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor

Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor

Cloning and characterization of the human V3 pituitary vasopressin receptor

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus

Molecular cloning of the receptor for human antidiuretic hormone

Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus

1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist

P304

2729-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI119098

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

1996-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14226035

http://www.w3.org/2001/XMLSchema#string

P698

8981918

http://www.w3.org/2001/XMLSchema#string

P921

P932

507737

http://www.w3.org/2001/XMLSchema#string